1887
Volume 2008, Issue 2
  • ISSN: 0253-8253
  • E-ISSN: 2227-0426

Abstract

We read with interest reports in Al Jazeera News(1) and Reuters News(2) of a new tuberculosis vaccine trial in South Africa and are pleased to learn that the Phase IIMVA85 A trial will begin shortly in the Western Cape, South Africa. The vaccine was developed by researchers at Oxford University and it works in tandem with BCG and acts as a booster to the older vaccine. Previous tests have already shown it produces a very high immune response but the key is to show it actually prevents disease. This vaccine passed Phase I clinical trials in Britain(3), and Africa (Gambia)(4), and is now starting Phase II clinical trials in Cape Town, South Africa(5). Although it is the first subunit TB vaccine that has entered clinical practice, it is NOT the first TB vaccine in clinical trials nor is it the first vaccine in Africa. This is the in clinical trials and in clinical trials in Africa(6). The MVA85A vaccine has just entered the Phase II clinical trials while an inactivated whole cell mycobacterial vaccine completed two Phase II clinical trials, one in Europe(7) (Finland) and the other in Africa(8) (Zambia) and also completed Phase III clinical trial in HIV+ve patients BCG primed in Africa(9).

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2008.2.6
2008-12-01
2019-12-11
Loading full text...

Full text loading...

References

  1. AlJazeera news, www.aljazeera.net .
  2. Reuters news.
  3. Bosch X. Tuberculosis vaccine trial gets underway. Lancet Infect Dis. 2004; 4::598.
    [Google Scholar]
  4. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Fletcher HA, Hill AV, Boosting BCG. with MVA85A, the first candidate subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb). 2005; 85::4752.
    [Google Scholar]
  5. McShane H, Pathan AA, Sander CR. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans. Nat Med. 2004; 10::12401244.
    [Google Scholar]
  6. Von Reyn CF. Tuberculosis vaccine trials. Lancet Infect Dis. 2005; 5:3:132.
    [Google Scholar]
  7. Vuola J, Ristola M, Cole B. Immunogenicity of an inactivated mycobacterial vaccine for the prevention of HIV-associated tuberculosis: A randomized, controlled trial. AIDS. 2003; 17::23512355.
    [Google Scholar]
  8. Waddell RD, Chintu C, Lein AD. Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccine for the prevention of HIV associated tuberculosis. Clin Infect Dis. 2000; 30:Suppl 3:S309S315.
    [Google Scholar]
  9. Matee M, Vuola J, Cole B, Bakari M, Arbeit RD, Horsburgh CR, Pallangyo K, Von Reyn CF. Baseline mycobacterial immune responses in HIV-infected adults primed with bacilli Calmette-Guerin during childhood and entering a tuberculosis booster vaccine trial. J infect Dis. 2007; 195:1:118123.
    [Google Scholar]
  10. Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, Hill AVS, Adegbola RA, McShane H. Early clinical trials with a new tuberculosis vaccine MVA85A in tuberculosis-endemic countries: issues in study design. The Lancet Infectious Diseases. 2006; 6:8:522528.
    [Google Scholar]
  11. Fine PEM, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunisation programmes. Geneva: WHO 1999.
    [Google Scholar]
  12. Fine PE. The BCG story: lessons from the past and implications for the future. Rev Infect Dis. 1989; 11::S353S359.
    [Google Scholar]
  13. Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: A meta-analysis. Int J Epidemiol. 1993; 22::11541158.
    [Google Scholar]
  14. Rodriguez LC, Pereira SM, Cunha SS. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 2005; 366::12901295.
    [Google Scholar]
  15. Black GF, Weir RE, Floyd S. BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: Two randomised controlled studies. Lancet. 2002; 359::13931401.
    [Google Scholar]
  16. Brandt L, Feino Cunha J, Weinreich Olsen A. Failure of the Mycobacterium bovis BCG vaccine: Some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun. 2002; 70::672678.
    [Google Scholar]
  17. Behr MA. BCG-different strains, different vaccines? Lancet Infect Dis. 2002; 2::8692.
    [Google Scholar]
  18. Comstock GW, Palmer CE. Long term results of BCGvaccination in the southern United States. Am Rev Respir Dis. 1966; 94::553568.
    [Google Scholar]
  19. pEpp st1e5in3 6P-1R5. 37B. C G vaccination and nutrition. Lancet. 1990; 335:.
    [Google Scholar]
  20. Skinner MA, Keen DL, Parlane NA, Yates GF, Buddie BM. Increased protection against bovine tuberculosis in the brushtailpossum (Trichosurus vulpecula) when BCG is administered with killed Mycobacterium vaccae. Tuberculosis. 2002; 82::1522.
    [Google Scholar]
  21. Marsh BJ, Von Reyn CF, Arbeit RD, Morin P. Immunization of HIV-infected adults with a three-dose series of inactivated Mycobacterium vaccae. Am J Med Sci. 1997; 313::377383.
    [Google Scholar]
  22. Johnson JL, Kamya RM, Okwera A, Loughlin AM, Nyole S, Horn DL. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. J Infect Dis. 2000; 181::13041312.
    [Google Scholar]
  23. Von Reyn CF, Marsh BJ, Waddell R, Lein AD, Tyaroha S, Morin P. Cellular immune responses to mycobacteria in healthy and human immunodeficiency virus positive subjects in the United States after a five dose schedule of Mycobacterium vaccaevaccine. Clin Infect Dis. 1998; 27::15171520.
    [Google Scholar]
  24. Waddell RD, Chintu C, Lein D, Zumla A, Karagas M, Baboo KS. Safety and immunogenicity of a 5 dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clin Infect Dis. 2000; 30:Suppl 3:S309S315.
    [Google Scholar]
  25. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: a randomized controlled trial. Lancet. 1999; 354::116119.
    [Google Scholar]
  26. McShane H, Pathan AA, Sander CR, Goonetilleke NP, Hill AV, Fletcher HA, Boosting BCG. with MVA85A, the first candidate Hill AV subunit vaccine for tuberculosis in clinical trials. Tuberculosis (Edinb). 2005; 85::4752.
    [Google Scholar]
  27. McShane H, Pathan AA, Sander CR. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG primed and naturally acquired anti-mycobacterial immunity in humans. Nat Med (2004) 10: pp 1240-1244.
  28. Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, Hill AV, Adegbola RA, McShane H. Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosisendemic countries: issues in study design. Lancet Infect Dis. 2006; 6:8:522528.
    [Google Scholar]
  29. Doherty TM. Real world TB vaccines: clinical trials in TBendemic regions. Vaccine. 2005; 23::21092114.
    [Google Scholar]
  30. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic S. Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci USA. 2000; 97::1385313858.
    [Google Scholar]
  31. Horwitz MA, Recombinant BCG. expressing Mycobacterium tuberculosis major extracellular proteins. Microbes Infect. 2005; 7::947954.
    [Google Scholar]
  32. Skeiky YA, Alder son MR, Ovendale PJ. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol. 2004; 172::76187628.
    [Google Scholar]
  33. National Institute of Allergy and Infectious Diseases. Preventing TB. Closing in: the long road to a TB vaccine http://www3.maid. nih.gov/news/focuson/tb/research/preventing/prevention_road.
  34. Skeiky YA, Sadoff JC. Advances in tuberculosis vaccine strategies. Nat Rev Microbiol. 2006; 4::469476.
    [Google Scholar]
  35. Grode L, Seller P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A, Mann P, Goosmann C, Bandermann S, Smith D, Bancroft GJ, Reyrat JM, Van Soolingen D, Raupach B, Kaufmann SH. Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guerin mutants that secrete listeriolysin. J Clin Invest. 2005;:24722479.
    [Google Scholar]
  36. Sambandamurthy VK, Derrick SC, Jalapathy KV, Chen B, Russell RG, Morris SL, Jacobs WR Jr. Long-Term Protection against Tuberculosis following Vaccination with a Severely Attenuated Double Lysine and Pantothenate Auxotroph of Mycobacterium tuberculosis. Infection and Immunity. 2005; 73:2:11961203.
    [Google Scholar]
  37. Delogu G, Li A, Repique C, Collins F, Morris SL. DNA vaccine combinations expressing either tissue plasminogen activator signal sequence fusion proteins or ubiquitin-conjugated antigens induce sustained protective immunity in a mouse model of pulmonary tuberculosis. Infect Immun. 2002; 70:1:292302.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2008.2.6
Loading
  • Article Type: Review Article
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error